Adlai Nortye names Christopher Liu head of investor and public relations

Adlai Nortye Group Ltd. (NASDAQ: ANL) announced on September 30, 2026 that it had appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. The company described itself as a clinical-stage biotechnology company focused on the development of innovative cancer therapies.¹

Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology, according to the release.¹ He most recently served as a Managing Director of equity research at Lucid Capital Markets covering biotechnology and oncology companies, and before that was a Director of equity research at Leerink Partners focused on oncology. He also held biotechnology research roles at Canaccord Genuity and Oppenheimer & Co., and received his Doctor of Pharmacy degree from the Ernest Mario School of Pharmacy at Rutgers University.¹

Carsten Lu, Chairman and Chief Executive Officer, was quoted welcoming Liu, saying his "deep understanding of oncology and extensive experience in the healthcare capital markets will be valuable as we continue to strengthen our engagement with the global investment community, enhance our external communications, and advance our pipeline."¹

Adlai Nortye said its pipeline spans two therapeutic areas. The first covers precision RAS pathway targeted therapies, including the oral pan-RAS(ON) inhibitor AN9025 and the CEACAM5-targeting ADC AN4035, engineered from the company's proprietary RASiCA (RAS Inhibitor Conjugated Antibody) platform¹. The second covers next-generation PD-1/L1 pathway modulating immunotherapies, including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells¹.

The announcement was filed with the U.S. Securities and Exchange Commission as a Form 6-K, signed by Yang Lu, Chief Executive Officer and Chairman of the Board of Directors, dated September 30, 2026.